Actorise 60mcg (Darbepoetin alfa)
Actorise 60mcg is indicated for the conditions as follows;
• The treatment in patients with Anemia associated with chronic kidney disease (CKD).
• The treatment in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
• The treatment in patients with Symptomatic Anemia associated with myelodysplastic syndromes (MDS).
DESCRIPTION
Darbepoetin alfa is a generic form of brand name of Actorise 60mcg
Actorise 60mcg injection causes the bone marrow to produce red blood cells. If the body does not produce suitable red blood cells, severe Anemia can occur. This frequentlyresults in people with chronic kidney failure whose kidneys are not proper working.
Actorise 60mcg may be prescribed for patients on kidney dialysis or for those not on dialysis.
Actorise 60mcg is a prescription drug which is used under the guidance of medical practioners.
INDICATION
Actorise 60mcg is indicated for the conditions as follows;
• The treatment in patients with Anemia associated with chronic kidney disease (CKD).
• The treatment in patients with Anemia is caused by chemotherapy cancer treatment but it is a support medication, it will not treat cancer
• The treatment in patients with Symptomatic Anemia associated with myelodysplastic syndromes (MDS).
MECHANISM OF ACTION
Darbepoetin consist of Recombinant human erythropoietin with sialic acid additions to have high stability; provoke erythropoiesis via division &differentiation of progenitor cells in bone marrow to activate the release of reticulocytes from the bone marrow into the bloodstream to form erythrocytes.
ADME PROPERTIES
Absorption
Low absorption
Distribution
Duration to high plasma concentration is 34 hr subcutaneously (SC)
Metabolism
For adult Bioavailability is 37% SC and children is 54% SC
Elimination
Volume of distribution is 0.06L/kg
Half-life is 46 hr (SC) and if IV then 21 hr.
DOSAGE MANAGEMENT
The dose of this medication will be varied for different patients.
Anemia from chronic kidney failure :
The dose adopted for adults and children – dose primarily based on body weight
The started recommended dose is 0.45 to 0.75 mcg/kg of body weight injected via IV or SC (under the skin) once a week or once every week.
Your doctor may adjust the dose as required.
Anemia from cancer chemotherapy :
Dose is based on body weight for adult
The starting recommended dose is 2.25mcg once every 3 weeks injected under the skin.
The dose for children and use should be decided by your doctor
SIDE EFFECTS
The side effects caused by Actorise 60mcg as follows :
Common side effects :
Dyspnea
Cough
During dialysis causes hypotension
Abdominal tenderness
Edema of the arms or legs.
Serious side effects :
Increased hypertension
Seizures
Severe allergic reaction: wheezing, dizziness, skin rash, itching
PRECAUTION
Devaluation of dose if Hgb increase exceeds 1 g/dL in any 2-week period
When treatment with Actorise 60mcg greater the mortality and/or raise risk of tumor development or recurrent in patients with cancer
The Actorise 60mcg has increased risk for seizures in patients with CKD; increase monitoring of these patients for changes in seizure frequency or premonitory symptoms.
Actorise 60mcg injection will leads toincrease mortality, myocardial infarction, stroke, and thromboembolism: Using ESAs to aims a haemoglobin level of higher than 11 g/dL raises the risk of serious adverse cardiovascular reactions
Actorise 60mcg injection will causes known porphyria, sickle cell Anemia, thalassemia in patients
If severe Anemia and low reticulocyte count results during treatment, detain treatment and check out for pure red cell aplasia.
DRUG INTERACTION
No drug interaction involved in the drug Actorise 60mcg Injection
CONTRAINDICATION
Unrestrained hypertension
Pure red cell aplasia occurred after treatment
Allergic problems
PREGNANCY
Pregnancy category is C
Usage of Actorise 60mcg:Animal studies have results in an adverse reaction and there are no adequate studies regarding usage in pregnant women
LACTATION
When using Actorise 60mcg during breastfeeding has no adequate studies in women for determine infant risk.
Considered potential risk before taking the drug while breastfeeding
STORAGE AND HANDLING
Store at 2°C – 8°C (36°F to 46°F)
Do not freeze
Store the drug from light and protect from moisture
MISSED DOSE
If dose is failed to take, then have it soon before next dose arrives or swap the dose and follow normal timing.
Must Consult with the physician.
Пока нет комментариев